# EDGAR Filing Document

**Accession Number:** 0001184228
**File Stem:** 0001193125-26-221988
**Filing Date:** 2026-5
**Character Count:** 7620
**Document Hash:** 8ee3cec8b10eb58d836d378c9de0444e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-221988.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001193125-26-221988

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eikon Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001861123
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 842807586
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95483
- **FILM NUMBER:** 26974698

**BUSINESS ADDRESS:**
- **STREET 1:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030
- **BUSINESS PHONE:** 341-777-0566

**MAIL ADDRESS:**
- **STREET 1:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PERLMUTTER ROGER M
- **CENTRAL INDEX KEY:** 0001184228

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**MAIL ADDRESS:**
- **STREET 1:** EIKON THERAPEUTICS, INC.
- **STREET 2:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** EIKON THERAPEUTICS, INC.

**Title of Class of Securities:** Common Stock, $0.0001 par value per share

**CUSIP Number:** —

**Date of Event Which Requires Filing of this Statement:** 02/04/2026

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>PERLMUTTER ROGER M | Names of Reporting Persons<br>PERLMUTTER ROGER M |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>2893171.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>2893171.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2893171.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2893171.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.2% | Percent of Class Represented by Amount in Row (9)<br>5.2% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** The shares listed in Rows 5 and 7 consist of (i) (a) 1,190,999 shares of common stock, $0.0001 par value per share (the Common Stock) of Eikon Therapeutics, Inc. (the Issuer) and (b) options to purchase 1,417,315 shares of Common Stock, exercisable within 60 days of March 31, 2026, held directly by Dr. Roger M. Perlmutter, and (ii) 284,857 shares of Common Stock held directly by Perlmutter Consulting, Inc. Dr. Perlmutter is the president and sole shareholder of Perlmutter Consulting, Inc. and may be deemed to have sole power to vote and to dispose its shares. The percentage in Row 11 is based on 54,138,555 shares of Common Stock outstanding on March 17, 2026 as reported by the Issuer on its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2026.

---

**Item 1(a). Name of Issuer:**
EIKON THERAPEUTICS, INC.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
230 HARRIET TUBMAN WAY, MILLBRAE, CALIFORNIA, 94030

**Item 2(a). Name of Person Filing:**
This Schedule is filed by Roger M. Perlmutter.

**Item 2(b). Address of Principal Business Office:**
230 Harriet Tubman Way, Millbrae CA 94030

**Item 2(c). Citizenship:**
See Row 4 of the cover page.

**Item 2(d). Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**Item 2(e). CUSIP Number:**
—

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

See Row 9 of the cover page.

**(b) Percent of class:**

See Row 11 of the cover page.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See Row 5 of the cover page.

**(ii) Shared power to vote or to direct the vote:**

See Row 6 of the cover page.

**(iii) Sole power to dispose or to direct the disposition of:**

See Row 7 of the cover page.

**(iv) Shared power to dispose or to direct the disposition of:**

See Row 8 of the cover page.

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**PERLMUTTER ROGER M**

**Date:** 05/13/2026

**By:** /s/ Roger M. Perlmutter

**Name & Title:** Roger M. Perlmutter